Perigon Wealth Management LLC Buys New Holdings in Natera, Inc. $NTRA

Perigon Wealth Management LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,293 shares of the medical research company’s stock, valued at approximately $622,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Trust Co. of Vermont purchased a new stake in Natera during the 2nd quarter valued at approximately $26,000. Reflection Asset Management purchased a new position in shares of Natera in the fourth quarter worth $29,000. Elevation Wealth Partners LLC bought a new position in shares of Natera during the second quarter worth $30,000. Palladiem LLC bought a new position in shares of Natera during the fourth quarter worth $31,000. Finally, Horizon Investments LLC bought a new position in shares of Natera during the third quarter worth $32,000. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Up 4.3%

Natera stock opened at $325.07 on Thursday. Natera, Inc. has a 52-week low of $156.71 and a 52-week high of $326.03. The firm’s fifty day moving average is $269.73 and its 200 day moving average is $228.01. The company has a market cap of $46.86 billion, a price-to-earnings ratio of -239.02 and a beta of 1.51.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s revenue was up 37.7% on a year-over-year basis. During the same period last year, the company posted ($0.74) EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of a number of research reports. Morgan Stanley reiterated an “overweight” rating and issued a $355.00 price target on shares of Natera in a report on Monday, August 10th. Wells Fargo & Company increased their price objective on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Robert W. Baird set a $348.00 target price on Natera in a report on Friday, August 7th. Finally, Royal Bank Of Canada boosted their target price on Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares in the company, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 181,045 shares of company stock worth $41,330,968 in the last quarter. Company insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.